Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway

Acta Pharmacologica Sinica

Volumn 35, Issue 6, 2014, Pages 716-726

  Zhang, Ling Ling ^a   Sui, Hai Juan ^a   Liang, Bing ^a   Wang, Han Ming ^a   Qu, Wen Hui ^a   Yu, Sheng Xue ^a   Jin, Ying ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimers disease; amyloid peptide; atorvastatin; cytokine; hippocampus; learning and memory; p38 MAPK; PSD 95; synapse; synaptophysin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ATORVASTATIN; MITOGEN ACTIVATED PROTEIN KINASE P38; AMYLOID BETA PROTEIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; NEUROPROTECTIVE AGENT; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN DEPLETION; RAT; SYNAPTIC TRANSMISSION; ANIMAL; CELL CULTURE; DRUG EFFECTS; MAZE TEST; MEMORY DISORDERS; METABOLISM; NERVE CELL; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SYNAPSE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; HEPTANOIC ACIDS; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; NEURONS; NEUROPROTECTIVE AGENTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84902292304     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.203     Document Type: Article

References (62)

1. Haass C,Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide, Nat Rev Mol Cell Biol, 2007 , 8,101-12.
2. Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008; 5: 233-43.
3. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100: 10417-22.
4. Chang L, Bakhos L, Wang Z, Venton DL, Klein WL. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci 2003; 20: 305-13.
5. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
6. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 41 6: 535-9.
7. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24: 10191-20 0.
8. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 2010; 13: 190-6.
9. Liu J, Chang L, Roselli F, Almeida OF, Gao X, Wang X, et al. Amyloidbeta induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors. J Alzheimers Dis 2010; 22: 541 -56.
10. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. PSD-95 involvement in maturation of excitatory synapses. Science 2000; 290: 1364-8.
11. Rao A, Kim E, Sheng M, Craig AM. Heterogeneity in the molecular composition of excitatory postsynaptic sites during development of hippocampal neurons in culture. J Neurosci 1998; 18: 1217-29.
12. Snyder EM , Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-8.
13. Shankar GM, Bloodgood BL, Town send M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-75.
14. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
15. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligomers inhibit long-term poten tiation through a mechanism involving excessive activation of extrasynaptic NR2Bcontaining NMDA receptors. J Neurosci 2011; 31: 6627-38.
16. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
17. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
18. Hosaka A, Araki W, Oda A, Tomidokoro Y, Tamaoka A. Statins reduce amyloid beta-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterolindependent mechanism in cultured neurons. Neurochem Res 2013; 38: 589-600.
19. Kurata T, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, et al. Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin. Neuroscience 2011; 197: 358-68.
20. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
21. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl c oenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
22. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebocontrolled, double-blind trial. Ann Neurol 2002; 52: 346-50.
23. Sparks DL,Sabbagh M,Connor D,Soares H,Lopez J,Stankovic G,et al.Statin therapy in Alzheimer's disease,Acta Neurol Scand Suppl,2006,185,78-86.
24. Li L, Cao D, Kim H, Lester R, Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006; 60: 729-39.
25. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005; 96: 69F-75F.
26. Clarke RM, O'Connell F, Lyons A, Lynch MA. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 2007; 52: 136-45.
27. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53.
28. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 2009; 17: 681-97.
29. Clarke RM, Lyons A, O'Connell F, Deighan BF, Barry CE, Anyakoha NG, et al. A pivotal role for interleukin-4 in atorvast atin-associated neuroprotection in rat brain. J Biol Chem 2008; 283: 1808-17.
30. Briones TL, Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 2011; 12: 124.
31. Jin Y, Sui HJ, Dong Y, Ding Q, Qu WH, Yu SX, et al. Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regu lating the Akt/mTOR and Akt/GSK-3beta signaling pathways. Acta Pharmacol Sin 2012; 33: 861-72.
32. Silva CG, Porciuncula LO, Canas PM, Oliveira CR, Cunha RA. Blockade of adenosine A(2A) recep tors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis 2007; 27: 182-9.
33. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, et al. A nov el p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007; 4: 21.
34. Zhu X, Mei M, Lee HG, Wang Y, Han J, Perry G, et al. P38 activation mediates amyloid-beta cytotoxicity. Neurochem Res 2005; 30: 791-6.
35. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133: 1328-41.
36. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 2009; 29: 400 4-15.
37. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 2008; 104: 457-68.
38. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of beta amyloid (1- 42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002; 924, 133-40.
39. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers . J Physiol 2006; 572: 477-92.
40. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dys function caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009; 29: 14741-51.
41. Yamada M, Chiba T, Sasabe J, Nawa M, Tajima H, Niikura T, et al . Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 2005; 164: 139-46.
42. Takeda S, Sato N, Niisato K, Takeuchi D, Kurinami H, Shinohara M, et al. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res 2009; 1280: 137-47.
43. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-93.
44. Lambert MP,Velasco PT,Chang L,Viola KL,Fernandez S,Lacor PN,et al. Monoclonal antibodies that target pathological assemblies of Abeta, J Neurochem, 2007, 100,23-35.
45. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004; 15: 667-72.
46. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, et al. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 2002; 19: 155-61.
47. Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005; 25: 299-307.
48. Lee ST, Chu K, Park JE, Hong NH, Im WS, Kang L, et al. Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. J Neurochem 2008; 104: 1190-200.
49. Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of longterm potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005; 22: 2827-32.
50. Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism. Brain Res Bull 2009; 80: 302-8.
51. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009; 34: 163-77.
52. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascu lar dementia. J Clin Immunol 1999; 19: 223-30.
53. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg P sychiatry 2003; 74: 1200-5.
54. Woiciechowsky C, Schoning B, Stoltenburg-Didinger G, Stockhammer F, Volk HD. Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranol ol and IL-10. Med Sci Monit 2004; 10: BR325-30.
55. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitricoxide synthase in astrocytes is interleukin-1beta-and tumor necrosis factor-alpha (TNFalpha )-dependent, and involves a TNFalpha receptorassociated factor-and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem 2000; 275: 7918-24.
56. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-betamediated cortical synaptic dysfunction. J Neurosci 2008; 28: 3521-30.
57. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol 2003; 183: 394-405.
58. Jin Y, Yan EZ, Fan Y, Zong ZH, Qi ZM, Li Z. Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. Acta Pharmacol Sin 2005; 26: 943-51.
59. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of th e p38MAPK pathway. Neurobiol Dis 2002; 11: 257-74.
60. Lee YB, Schrader JW, Kim SU. p38 map kinase regulates TNFalpha production in human astrocytes and microglia by multiple mechanisms. Cytokine 2000; 12: 874-80.
61. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's dis ease: potential significance for tau protein phosphorylation. Neurochem Int 2001; 39: 341-8.
62. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23: 1605-11.